Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for 90 percent of all liver cancers. New Cases & Deaths

More than Approximately 1 in 12 cancer Liver cancer is the third leading cause of Median Age deaths are due to liver cancer. cancer mortality worldwide and occurs 905,600 more often in men than women. people around the world are diagnosed 632,300 65 68 with liver cancer each year. 273,400 At Diagnosis At Death cases per year Source: GLOBOCAN 2020 Source: SEER 2014-2018

Global Incidence Staging & Survival Rates

Estimated numbers of annual liver cancer cases by region: HCC in adults is often diagnosed in later stages, which results in relatively low five-year survival North America Europe Asia rates. Liver cancer five-year relative survival 46,600 87,600 657,000 rates vary by stage at diagnosis: Localized 35% Central America Africa & the Caribbean Regional 12%

70,500 Distant 15,200 Oceania 7% South America 4,400 Unknown 3% 0 5 10 15 20 25 30 35 24,300 Source: GLOBOCAN 2020 Source: SEER 2011-2017

Common Risk Factors Between 80 and 90 percent of all HCC cases worldwide are caused by infection with the Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). Other common risk factors include:

Chronic HCV/HBV Cirrhosis Heavy Gender Race and Certain Genetic Type 2 Obesity Non-Alcoholic Infection Alcohol Use Ethnicity Syndromes Diabetes Steatohepatitis (Nash)

Signs & Symptoms Treatment Options

A patient’s treatment options are largely dependent on stage of Unintended weight loss Abdominal pain disease and may include: and/or swelling Loss of appetite Itching Nausea or vomiting

Enlarged liver Yellowing of the Tumor Targeted Radiation Surgery Chemotherapy Ablation or Immunotherapy Drug and/or spleen skin and eyes Therapy Embolization Therapy

© 2021 Bristol Myers Squibb